The pharmaceutical stock is surging after providing preliminary results for the fourth quarter of 2019.
These two renewable energy stocks offer investors a way to own a piece of the ongoing energy transition, which will accelerate in the 2020s.
Investors might be getting a little carried away with news from the FDA.
Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.
These two industry leaders pay handsome dividends and aren't getting enough respect from the market, which puts them in play for income investors and value investors alike.
The business grew only slightly, but the company invested in key areas to support future growth.
The company announced a new development plan with Bristol-Myers Squibb.
The company announced the pricing of a public stock offering.
Investors ran away after the business provided preliminary full-year 2019 results.
It was a trying year for the generic drug manufacturer. Can a combination with Pfizer help to soothe beleaguered investors?
The medical device developer kept its growth engine humming along last year. It expects double-digit growth again in 2020.
As its stock chart suggests, the liquid biopsy pioneer crushed it on nearly every metric last year.
The stock lost value last year, but not 40.5%. The breakup of DowDuPont is reflected in the stock chart, but so, too, are sensible concerns over a major source of uncertainty.
The gene-editing pioneer reported data from the first two patients dosed with its first drug candidate. The early results didn't disappoint.
The pharmaceutical company's lead drug product continued to underwhelm. Just-released preliminary fourth-quarter results show much of the same.
The fuel cell developer had a trying year financially, but a strong third-quarter performance instilled optimism in investors.
The company announced plans to slash its head count and go all in on a single gene therapy. Is that wise or stubborn?
The RNAi drug developer tickled investors with promising clinical data.
All of the share price gains came after September -- and for good reason.
These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.